<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Natalizumab</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00108</strong>&#160; (BIOD00083, BTD00083)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (<span class="caps">PML</span>). It was returned to market July, 2006.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00108.png?1266600376"><img alt="Db00108" src="/system/protein_structures/thumb/DB00108.png?1266600376"></a></td></tr><tr><th>Protein chemical formula</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein average weight</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Anti-alpha4 integrin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Anti-VLA4</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Tysabri</td><td>Elan Pharmaceuticals and Biogen Idec</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>189261-10-7</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For treatment of multiple sclerosis.</td></tr><tr><th>Pharmacodynamics</th><td>In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain. &#945;4-integrin is required for white blood cells to move into organs, therefore, natalizumab prevents these immune cells from crossing blood vessel walls to reach affected organs thereby decreasing inflamation.</td></tr><tr><th>Mechanism of action</th><td>Binds to the &#945;4-subunit of &#945;4b 1 and &#945;4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the &#945;4-mediated adhesion of leukocytes to their counter-receptor(s).</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>5.7 &#177; 1.9 L [Multiple Sclerosis (MS) Patients]</li>
	<li>5.2 &#177; 2.8 L [Crohn&#8217;s Disease (CD) Patients]</li>
</ul></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Most likely removed by opsonization via the reticuloendothelial system when bound to leukocytes.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>11 &#177; 4 days</td></tr><tr><th>Clearance</th><td><ul>
	<li>16 +/- 5 mL/hour [patients with MS who did not have <span class="caps">PML</span> receiving the repeat IV administration of a 300 mg dose]</li>
	<li>22 +/- 22 mL/hour [Patients with Crohn&#8217;s Disease receiving the repeat IV administration of a 300 mg dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.biogenidec.com">Biogen Idec Inc.</a></li>
<li><a href="http://www.elan.com">Elan Pharmaceuticals Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Tysabri 300 mg/15 ml vial</td><td>207.31USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>61 &#176;C (FAB fragment), 71 &#176;C (whole mAb)</td><td>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</td></tr></table></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn&#8217;s disease. N Engl J Med. 2003 Jan 2;348(1):24-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12510039">Pubmed</a></li>
	<li>Patent Information <a href="http://www.patentstorm.us/patents/5840299/fulltext.html">Link</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164747191" target="_blank">PA164747191 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2286386" target="_blank">2286386 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/tysabri.htm" target="_blank">http://www.rxlist.com/cgi/generic/tysabri.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/natalizumab.html" target="_blank">http://www.drugs.com/cdi/natalizumab.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Natalizumab" target="_blank">Natalizumab <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>AHFS Codes</th><td><ul><li>92:00.00</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1IGT" target="_blank">1IGT <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00108.pdf?1265922803">show</a>(96 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05773">ado-trastuzumab emtansine</a></td><td>Avoid combination due to the increased risk of infection.</td></tr><tr><td><a href="/drugs/DB00290">Bleomycin</a></td><td>Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.</td></tr><tr><td><a href="/drugs/DB08870">Brentuximab vedotin</a></td><td>Avoid combination due to the increased risk of concurrent infection.</td></tr><tr><td><a href="/drugs/DB06168">Canakinumab</a></td><td>Avoid combination due to the increased risk of infection.

</td></tr><tr><td><a href="/drugs/DB00958">Carboplatin</a></td><td>Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.</td></tr><tr><td><a href="/drugs/DB00262">Carmustine</a></td><td>Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.</td></tr><tr><td><a href="/drugs/DB08904">Certolizumab pegol</a></td><td>Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB00291">Chlorambucil</a></td><td>Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.</td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.</td></tr><tr><td><a href="/drugs/DB00242">Cladribine</a></td><td>Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. </td></tr><tr><td><a href="/drugs/DB00631">Clofarabine</a></td><td>Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. </td></tr><tr><td><a href="/drugs/DB06674">golimumab</a></td><td>Avoid combination due to the increased chance of infection.

</td></tr><tr><td><a href="/drugs/DB04865">Homoharringtonine</a></td><td>Avoid combination due to the increased risk of infection.
</td></tr><tr><td><a href="/drugs/DB01229">Paclitaxel</a></td><td>Avoid combination due to the increased risk of infection.
</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.</td></tr><tr><td><a href="/drugs/DB00853">Temozolomide</a></td><td>The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08880">Teriflunomide</a></td><td>Avoid combination due to the increased risk of infection.

</td></tr><tr><td><a href="/drugs/DB01041">Thalidomide</a></td><td>Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.</td></tr><tr><td><a href="/drugs/DB04572">Thiotepa</a></td><td>The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00352">Tioguanine</a></td><td>The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination due to the increased risk of infection.

</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00081">Tositumomab</a></td><td>The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00385">Valrubicin</a></td><td>Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>